Efficacy of R±BEACOP regimen in patients with
poor-prognosis lymphoma.
10.11817/j.issn.1672-7347.2015.08.006
- Author:
Fei DONG
1
;
Yifan PANG
1
;
Jing WANG
1
;
Xiaoyan KE
1
Author Information
1. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Bleomycin;
therapeutic use;
Cyclophosphamide;
therapeutic use;
Doxorubicin;
therapeutic use;
Etoposide;
therapeutic use;
Humans;
Lymphoma;
classification;
diagnosis;
drug therapy;
Prednisone;
therapeutic use;
Procarbazine;
therapeutic use;
Prognosis;
Retrospective Studies;
Rituximab;
therapeutic use;
Vincristine;
therapeutic use
- From:Journal of Central South University(Medical Sciences)
2015;40(8):858-863
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the efficacy of cyclophosphamideplus, epirubicin, vincristine, prednisone plus etoposide and/or bleomycin, with or without rituximab (R±BEACOP) regimen in patient with poor-prognosis lymphoma.
METHODS:A total of 89 patients, who had poor-prognosis lymphoma and received at least 1 cycle of R±BEACOP regimen during 2002 to 2012, were enrolled and analyzed by a retrospective study.
RESULTS:The rate of complete response was 62.9% (56 patients). The efficacy of Hodgkin lymphoma (HL) and T/NK NHL was better than that of other types of lymphoma. There was no significant difference in efficacy among the patients with different age, stage or international prognosis index (IPI) (all P>0.05).
CONCLUSION:R±BEACOP regimen is effective in some patients with poor prognosis, especially in HL patients. Thus, multicenter prospective study regarding the R±BEACOP regimen needs to be done to further test its efficacy.
